Stock Analysis Report

GlaxoSmithKline Consumer Healthcare

Executive Summary

GlaxoSmithKline Consumer Healthcare Limited manufactures and sells malt based foods, protein rich foods, and cereal based beverages in India.


Earnings grew by 27.2% over the past year

Pays a reliable dividend of 1.08%

Risk Analysis

No risks detected for 500676 from our risk checks.

Snowflake Analysis

Outstanding track record with flawless balance sheet and pays a dividend.

Similar Companies

Share Price & News

How has GlaxoSmithKline Consumer Healthcare's share price performed over time and what events caused price changes?

Latest Share Price and Events

Stable Share Price: 500676 has not had significant price volatility in the past 3 months.

Market Performance

7 Day Return




IN Food


IN Market

1 Year Return




IN Food


IN Market

Return vs Industry: 500676 exceeded the Indian Food industry which returned 23.7% over the past year.

Return vs Market: 500676 exceeded the Indian Market which returned 9.5% over the past year.

Shareholder returns

7 Day-0.2%-0.2%-0.08%
30 Day9.1%2.0%0.01%
90 Day10.7%11.6%3.2%
1 Year34.9%33.0%25.4%23.7%11.5%9.5%
3 Year93.3%86.0%79.6%74.4%23.6%16.7%
5 Year77.1%67.1%128.6%117.7%35.5%22.9%

Price Volatility Vs. Market

How volatile is GlaxoSmithKline Consumer Healthcare's share price compared to the market and industry in the last 5 years?

Simply Wall St News


Is GlaxoSmithKline Consumer Healthcare undervalued compared to its fair value and its price relative to the market?


Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: 500676 (₹9679.45) is trading above our estimate of fair value (₹2602.36)

Significantly Below Fair Value: 500676 is trading above our estimate of fair value.

Price To Earnings Ratio

PE vs Industry: 500676 is poor value based on its PE Ratio (35.2x) compared to the Food industry average (13.9x).

PE vs Market: 500676 is poor value based on its PE Ratio (35.2x) compared to the Indian market (13.3x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 500676's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: 500676 is overvalued based on its PB Ratio (9.8x) compared to the IN Food industry average (0.9x).

Next Steps

Future Growth

How is GlaxoSmithKline Consumer Healthcare forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?


Forecasted Food, Beverage & Tobacco industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as GlaxoSmithKline Consumer Healthcare has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Next Steps

Past Performance

How has GlaxoSmithKline Consumer Healthcare performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 500676 has high quality earnings.

Growing Profit Margin: 500676's current net profit margins (23.2%) are higher than last year (19.4%).

Past Earnings Growth Analysis

Earnings Trend: 500676's earnings have grown by 13.1% per year over the past 5 years.

Accelerating Growth: 500676's earnings growth over the past year (27.2%) exceeds its 5-year average (13.1% per year).

Earnings vs Industry: 500676 earnings growth over the past year (27.2%) exceeded the Food industry 20.6%.

Return on Equity

High ROE: 500676's Return on Equity (27.8%) is considered high.

Return on Assets

Return on Capital Employed

Next Steps

Financial Health

How is GlaxoSmithKline Consumer Healthcare's financial position?

Financial Position Analysis

Short Term Liabilities: 500676's short term assets (₹53.3B) exceed its short term liabilities (₹17.8B).

Long Term Liabilities: 500676's short term assets (₹53.3B) exceed its long term liabilities (₹2.0B).

Debt to Equity History and Analysis

Debt Level: 500676 is debt free.

Reducing Debt: 500676 had no debt 5 years ago.

Debt Coverage: 500676 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 500676 has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet

Inventory Level: 500676 has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 500676's debt is covered by short term assets.

Next Steps


What is GlaxoSmithKline Consumer Healthcare's current dividend yield, its reliability and sustainability?


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 500676's dividend (1.08%) is higher than the bottom 25% of dividend payers in the Indian market (0.59%).

High Dividend: 500676's dividend (1.08%) is low compared to the top 25% of dividend payers in the Indian market (2.58%).

Stability and Growth of Payments

Stable Dividend: 500676's dividends per share have been stable in the past 10 years.

Growing Dividend: 500676's dividend payments have increased over the past 10 years.

Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (38.2%), 500676's dividend payments are well covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Navneet Saluja 0





Mr. Navneet Saluja is India Sub-Continent, Area General Manager and Managing Director and Director at GlaxoSmithKline Consumer Healthcare Limited since January 1, 2018. He has multi sectoral experience inc ...

CEO Compensation Analysis

Compensation vs Market: Navneet's total compensation ($USD1.55M) is above average for companies of similar size in the Indian market ($USD1.14M).

Compensation vs Earnings: Navneet's compensation has increased by more than 20% in the past year.

Leadership Team

Navneet Saluja
ISC Area GM2.1yrs₹111.31mno data
Anup Dhingra
Director of Operations & Executive Director3.4yrs₹64.78mno data
Shanu Saksena
Company Secretary and Area Ethics & Compliance Officer3.5yrs₹15.55mno data
Nitin Mathur
Interim Head of Finance - ISC0yrsno datano data
Surinder Kumar
Director of Legal0yrs₹3.20mno data
Rahul Kapoor
Executive Vice President of Human Resources1.7yrsno datano data
Narendra Vutla
Head of Product Optimization Center of Excellence0yrsno datano data
Sridhar Kameshwaran
Executive Vice President of R&D International4.6yrsno datano data
Deepa Dey
Head of Communications - ISC7.1yrsno datano data
Arun Mishra
Executive VP & Head of Regulatory Affairs - ISC 3.9yrsno datano data


Average Tenure

Experienced Management: 500676's management team is considered experienced (3.5 years average tenure).

Board Members

Navneet Saluja
ISC Area GM2.1yrs₹111.31mno data
Anup Dhingra
Director of Operations & Executive Director3.4yrs₹64.78mno data
Sangeeta Talwar
Independent Director5.5yrs₹2.50mno data
Patnam Dwarakanath
Non-Executive Chairman1.7yrs₹2.23mno data
Pradeep Bhide
Independent Director0.8yrsno datano data
Subramanian Madhavan
Additional Independent Director1.4yrs₹550.00kno data


Average Tenure


Average Age

Experienced Board: 500676's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

GlaxoSmithKline Consumer Healthcare Limited's company bio, employee growth, exchange listings and data sources

Key Information

  • Name: GlaxoSmithKline Consumer Healthcare Limited
  • Ticker: 500676
  • Exchange: BSE
  • Founded: 1958
  • Industry: Packaged Foods and Meats
  • Sector: Food, Beverage & Tobacco
  • Market Cap: ₹407.074b
  • Shares outstanding: 42.06m
  • Website:

Number of Employees


  • GlaxoSmithKline Consumer Healthcare Limited
  • One Horizon Centre
  • 24-25 Floor
  • Gurugram
  • Haryana
  • 122002
  • India


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
500676BSE (Mumbai Stock Exchange)YesEquity SharesININRApr 1999
GSKCONSNSEI (National Stock Exchange of India)YesEquity SharesININRApr 1999


GlaxoSmithKline Consumer Healthcare Limited manufactures and sells malt based foods, protein rich foods, and cereal based beverages in India. The company offers health food drinks and biscuits under the Horlicks, Boost, Viva, and Maltova brand names; Ostocalcium, a calcium supplement; ENO, an antacid for acidity; Crocin, a non–prescription analgesics drug; and Iodex, a balm for neck/shoulder pain, back pain, joint pain, sprain, etc. It also provides Crocin Cold & Flu, which provides relief from headache, body aches and pains, and sore throat, as well as pain associated with sinusitis, nasal, and sinus congestion; and Otrivin, a nasal decongestant that provides relief from blocked nose. In addition, the company offers toothpaste for sensitive teeth under the Sensodyne name; and prescription medicines for a range of therapeutic areas, as well as vaccines for the prevention of life-threatening diseases. It also exports its products to Bangladesh, Sri Lanka, the Middle East, Myanmar, Kenya, Mauritius, and Pakistan. GlaxoSmithKline Consumer Healthcare Limited was incorporated in 1958 and is headquartered in Gurugram, India. 

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/22 12:40
End of Day Share Price2020/02/20 00:00
Annual Earnings2019/03/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.